7 Analysts Have This To Say About NeoGenomics
Portfolio Pulse from Benzinga Insights
Seven analysts have recently updated their ratings on NeoGenomics (NASDAQ:NEO), with a mix of bullish and indifferent stances. The average 12-month price target is now $18.14, down from the previous $19.00. Analysts from firms including Needham, Morgan Stanley, Goldman Sachs, and Piper Sandler have maintained or adjusted their ratings and price targets. NeoGenomics operates cancer-focused genetic testing labs and has shown a revenue growth of 17.99% as of September 30, 2023, but struggles with net margin and ROE. The company's debt-to-equity ratio is below industry average, indicating less reliance on debt.
December 28, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NeoGenomics has received varied analyst ratings with an average price target of $18.14, reflecting a downward revision from $19.00. The company's strong revenue growth contrasts with its profitability issues.
The mixed analyst ratings and the reduction in the average price target suggest uncertainty, which could lead to a neutral short-term impact on NeoGenomics' stock price. The strong revenue growth is positive, but profitability issues may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100